Author:
Perez Eduardo A.,Skinner Michael
Publisher
Springer Berlin Heidelberg
Reference74 articles.
1. Raue F, Frank-Raue K. Update multiple endocrine neoplasia type 2. Fam Cancer. 2010. doi: 10.1007/s10689-010-9320-2 .
2. Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, Blijham G, van Veen JM, van Gils AP, de Wit MJ, Zewald RA, Berends MJ, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2a. N Engl J Med. 1994;331(13):828–35.
3. Machens A. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med. 2004’350(9):943. doi: 10.1056/NEJM200402263500917 . (350/9/943 [pii]).
4. Ponder BA, Ponder MA, Coffey R, Pembrey ME, Gagel RF, Telenius-Berg M, Semple P, Easton DF. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet. 1988;1(8582):397–401.
5. Donovan DT, Levy ML, Furst EJ, Alford BR, Wheeler T, Tschen JA, Gagel RF. Familial cutaneous lichen amyloidosis in association with multiple endocrine neoplasia type 2a: A new variant. Henry Ford Hosp Med J. 1989;37(3–4):147–50.